Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1089/pop.2020.0230 http://scihub22266oqcxt.onion/10.1089/pop.2020.0230 33031013!7875135!33031013     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Popul+Health+Manag 2021 ; 24 (S1): S43-S51 Nephropedia Template TP {{tp|p=33031013|t=2021. The Opioid Epidemic Within the COVID-19 Pandemic: Drug Testing in 2020 |pdf=|usr=}}{{33031013}} gab.com Text The Opioid Epidemic Within the COVID-19 Pandemic: Drug Testing in 2020 JO: Popul Health Manag http://www.kidney.de/pget.php?&tw=1&pmid=33031013 #FOAvip The convergence of the opioid epidemic and the coronavirus disease 2019 (COVID-19) pandemic has created new health care challenges. The authors analyzed changes in clinical drug testing patterns and results at a national clinical laboratory, comparing data obtained before and during the pandemic. Testing for prescription and illicit drugs declined rapidly during the pandemic, with weekly test volumes falling by approximately 70% from the baseline period to the trough (the week beginning March 29) before rising in subsequent weeks. Among individuals tested, positivity increased by 35% for non-prescribed fentanyl and 44% for heroin during the pandemic. Positivity for non-prescribed fentanyl increased significantly among patients positive for other drugs: by 89% for specimens positive for amphetamines; 48% for benzodiazepines; 34% for cocaine; and 39% for opiates (P < 0.01 for all comparisons). These findings suggest significant increases in dangerous drug combinations. Positivity for non-prescribed use of many other drugs remained consistent or declined for some drugs, relative to pre-pandemic patterns. Models adjusting for potential confounding variables, including medication-assisted treatment and treatment at a substance use disorder facility indicated that the risk for non-prescribed fentanyl positivity rose by more than 50% during the pandemic. In summary, these findings demonstrate decreased drug testing overall, with increased positivity for high-risk drugs and dangerous drug combinations. The convergence of the drug abuse epidemic and COVID-19 pandemic has led to an increased need for health care and public health resources dedicated to supporting vulnerable patients and addressing the underlying causes of these disturbing trends. Twit Text FOAVip The Opioid Epidemic Within the COVID-19 Pandemic: Drug Testing in 2020 ????Popul Health Manag http://www.kidney.de/pget.php?&tw=1&pmid=33031013 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33031013 #FOAvip English Wikipedia <ref>{{Cite pmid|33031013}}</ref> The Opioid Epidemic Within the COVID-19 Pandemic: Drug Testing in 2020 #MMPMID33031013 Niles JK; Gudin J; Radcliff J; Kaufman HW Popul Health Manag 2021[Feb]; 24 (S1): S43-S51 PMID33031013show ga The convergence of the opioid epidemic and the coronavirus disease 2019 (COVID-19) pandemic has created new health care challenges. The authors analyzed changes in clinical drug testing patterns and results at a national clinical laboratory, comparing data obtained before and during the pandemic. Testing for prescription and illicit drugs declined rapidly during the pandemic, with weekly test volumes falling by approximately 70% from the baseline period to the trough (the week beginning March 29) before rising in subsequent weeks. Among individuals tested, positivity increased by 35% for non-prescribed fentanyl and 44% for heroin during the pandemic. Positivity for non-prescribed fentanyl increased significantly among patients positive for other drugs: by 89% for specimens positive for amphetamines; 48% for benzodiazepines; 34% for cocaine; and 39% for opiates (P < 0.01 for all comparisons). These findings suggest significant increases in dangerous drug combinations. Positivity for non-prescribed use of many other drugs remained consistent or declined for some drugs, relative to pre-pandemic patterns. Models adjusting for potential confounding variables, including medication-assisted treatment and treatment at a substance use disorder facility indicated that the risk for non-prescribed fentanyl positivity rose by more than 50% during the pandemic. In summary, these findings demonstrate decreased drug testing overall, with increased positivity for high-risk drugs and dangerous drug combinations. The convergence of the drug abuse epidemic and COVID-19 pandemic has led to an increased need for health care and public health resources dedicated to supporting vulnerable patients and addressing the underlying causes of these disturbing trends. |*COVID-19[MESH] |*Opioid-Related Disorders/diagnosis/epidemiology[MESH] |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Analgesics, Opioid/urine[MESH] |Female[MESH] |Fentanyl/urine[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Opioid Epidemic/*statistics & numerical data[MESH] |Pandemics[MESH] |SARS-CoV-2[MESH] |Substance Abuse Detection/*statistics & numerical data[MESH] |Substance-Related Disorders/diagnosis/epidemiology[MESH]The Opioid Epidemic Within the COVID-19 Pandemic: Drug Testing in 2020(epmc).pdf DeepDyve Pubget Overpricing